The past, present and future of antifolates in the treatment of Plasmodium falciparum infection.
暂无分享,去创建一个
[1] Synthesis of substituted indole derivatives as a new class of antimalarial agents. , 2005, Bioorganic & medicinal chemistry letters.
[2] K. Srivastava,et al. Synthesis of substituted indole derivatives as a new class of antimalarial agents. , 2005, Bioorganic & medicinal chemistry letters.
[3] C. Plowe,et al. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. , 1997, Parasitology today.
[4] J. Golenser,et al. Plasmodium falciparum: in vitro induction of resistance to aminopterin. , 1981, Experimental parasitology.
[5] A. Dicko,et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. , 2005, The Journal of infectious diseases.
[6] A. Sowunmi,et al. Open randomized study of pyrimethamine–sulphadoxine vs. pyrimethamine–sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children , 2004, Tropical medicine & international health : TM & IH.
[7] C. Sibley,et al. Efficacies of Lipophilic Inhibitors of Dihydrofolate Reductase against Parasitic Protozoa , 2001, Antimicrobial Agents and Chemotherapy.
[8] David A. Fidock,et al. Antimalarial drug discovery: efficacy models for compound screening , 2004, Nature Reviews Drug Discovery.
[9] A. Nzila,et al. Sulfa drugs strike more than once. , 2004, Trends in parasitology.
[10] D. G. Davey,et al. Studies on synthetic antimalarial drugs; some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. , 1945, Annals of tropical medicine and parasitology.
[11] T. Wellems,et al. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[12] J. E. Hyde,et al. Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to Plasmodium. , 2005, Trends in parasitology.
[13] N. Tomioka,et al. Lead discovery of inhibitors of the dihydrofolate reductase domain of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. , 1997, Biochemical and biophysical research communications.
[14] J. E. Hyde,et al. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance , 1997, Parasitology.
[15] R. Degowin,et al. Clinical experience with sulphadiazine and pyrimethamine in the treatment of persons experimentally infected with chloroquine-resistant Plasmodium falciparum. , 1967, Annals of tropical medicine and parasitology.
[16] E. Petersen. Malaria chemoprophylaxis: when should we use it and what are the options? , 2004, Expert review of anti-infective therapy.
[17] I. Sia,et al. A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[18] A. Jung,et al. Mechanisms of sulfadoxine resistance in Plasmodium falciparum. , 1986, Molecular and biochemical parasitology.
[19] K. Srivastava,et al. Antimalarial activity of 2,4,6-trisubstituted pyrimidines. , 2005, Bioorganic & medicinal chemistry letters.
[20] J. Zurlo,et al. Trimethoprim-sulfamethoxazole revisited. , 2003, Archives of internal medicine.
[21] N. White,et al. Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[22] A. Nzila,et al. Therapeutic potential of folate uptake inhibition in Plasmodium falciparum. , 2004, Trends in parasitology.
[23] C. Sibley,et al. Novel alleles of Plasmodium falciparum dhfr that confer resistance to chlorcycloguanil. , 2005, Molecular and biochemical parasitology.
[24] C. Sibley,et al. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[25] G. Hitchings,et al. Antagonists of nucleic acid derivatives. VI. Purines. , 1951, The Journal of biological chemistry.
[26] W. Watkins,et al. Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. , 2005, The American journal of tropical medicine and hygiene.
[27] W. Peters. Malaria. Chemoprophylaxis and chemotherapy. , 1971, British medical journal.
[28] A. Jackman. Antifolate Drugs in Cancer Therapy , 1999, Cancer Drug Discovery and Development.
[29] A. Cowman,et al. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[30] K. Srivastava,et al. Syntheses of 2,4,6-trisubstituted triazines as antimalarial agents. , 2005, Bioorganic & medicinal chemistry letters.
[31] D. Banerjee,et al. Resistance Mechanisms to Methotrexate in Tumors , 1996, Stem cells.
[32] W. Peters. Chemoprophylaxis and chemotherapy. , 1971 .
[33] A. Nzila,et al. Chemosensitization of Plasmodium falciparum by Probenecid In Vitro , 2003, Antimicrobial Agents and Chemotherapy.
[34] A. Nzila,et al. Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa , 2003, Malaria Journal.
[35] C. Plowe,et al. Mechanisms of Resistance of Malaria Parasites to Antifolates , 2005, Pharmacological Reviews.
[36] A. Sowunmi,et al. Comparative effects of pyrimethamine–sulfadoxine, with and without probenecid, on Plasmodium falciparum gametocytes in children with acute, uncomplicated malaria , 2004, Annals of tropical medicine and parasitology.
[37] Yongyuth Yuthavong,et al. Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. , 2004, Journal of medicinal chemistry.
[38] A. Cowman,et al. Functional genomics: identifying drug targets for parasitic diseases. , 2003, Trends in parasitology.
[39] W. Sirawaraporn,et al. Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum. , 2002, Journal of medicinal chemistry.
[40] W. Watkins,et al. The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug. , 1999, The American journal of tropical medicine and hygiene.
[41] J. E. Hyde,et al. Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. , 2005, Trends in parasitology.
[42] Yongyuth Yuthavong,et al. Stoichiometric selection of tight-binding inhibitors by wild-type and mutant forms of malarial (Plasmodium falciparum) dihydrofolate reductase. , 2005, Analytical chemistry.
[43] Yongyuth Yuthavong,et al. Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. , 2002, Molecular and biochemical parasitology.
[44] J. E. Hyde,et al. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization , 1997, Molecular microbiology.
[45] I. Adagu,et al. Co-trimoxazole compared with sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in Kenyan children. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[46] M. Walkinshaw,et al. Characterization, crystallization and preliminary X-ray analysis of bifunctional dihydrofolate reductase-thymidylate synthase from Plasmodium falciparum. , 2004, Acta crystallographica. Section D, Biological crystallography.
[47] F. M. Hanes. DIAGNOSTIC CRITERIA AND RESISTANCE TO THERAPY IN THE SPRUE SYNDROME , 1942 .
[48] D. G. Davey,et al. A Metabolite of ‘Paludrine’ with High Antimalarial Activity , 1951, Nature.
[49] A. Sowunmi,et al. Comparative efficacy of chloroquine and cotrimoxazole in the treatment of acute uncomplicated falciparum malaria in Nigerian children. , 2002, The Central African journal of medicine.
[50] S. Chusacultanachai,et al. Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors , 2004, Parasitology.
[51] S. Krungkrai,et al. Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. , 1992, Biochemical pharmacology.
[52] T. Holtz,et al. Efficacy of trimethoprim-sulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. , 2005, The American journal of tropical medicine and hygiene.
[53] K. Srivastava,et al. Antimalarial activity and synthesis of new trisubstituted pyrimidines. , 2005, Bioorganic & medicinal chemistry letters.
[54] Yongyuth Yuthavong,et al. Basis for antifolate action and resistance in malaria. , 2002, Microbes and infection.
[55] W. Sirawaraporn,et al. Pyrimethamine analogs as strong inhibitors of double and quadruple mutants of dihydrofolate reductase in human malaria parasites. , 2003, Organic & biomolecular chemistry.
[56] K. Kain,et al. Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[57] P. Rathod,et al. Selection and characterization of 5-fluoroorotate-resistant Plasmodium falciparum , 1994, Antimicrobial Agents and Chemotherapy.
[58] A. Sowunmi,et al. Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment. , 2004, Parasite.
[59] D. Warhurst,et al. Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210. , 2001, Molecular and biochemical parasitology.
[60] T. Triglia,et al. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[61] W. Watkins,et al. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[62] P. Rathod,et al. Potent and Selective Activity of a Combination of Thymidine and 1843U89, a Folate-Based Thymidylate Synthase Inhibitor, against Plasmodium falciparum , 2000, Antimicrobial Agents and Chemotherapy.
[63] R. Black. Malaria in the Australian army in South Vietnam: successful use of a proguanil-dapsone combination for chemoprophylaxis of chloroquine-resistant falciparum malaria. , 1973, The Medical journal of Australia.
[64] J. E. Hyde,et al. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine‐resistant malaria , 1998, The EMBO journal.
[65] A. Hall,et al. Comparison of diaminodiphenylsulphonepyrimethamine and sulfadoxine-pyrimethamine combinations in the treatment of falciparum malaria in Thailand. , 1975, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[66] D. Koech,et al. INADEQUACY OF CHLORPROGUANIL 20 mg PER WEEK AS CHEMOPROPHYLAXIS FOR FALCIPARUM MALARIA IN KENYA , 1987, The Lancet.
[67] M. Hurly. Potentiation of pyrimethamine by sulphadiazine in human malaria. , 1959, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[68] Z. Premji,et al. Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites. , 2004, The Journal of infectious diseases.
[69] K. Rieckmann,et al. Effects of diaphenylsulphone (dapsone) against Plasmodium vivax of South West Pacific origin. , 1968, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[70] H. Webster,et al. Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. , 1992, The American journal of tropical medicine and hygiene.
[71] K. Rieckmann,et al. Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. , 2001, Journal of medicinal chemistry.
[72] G. E. Foster,et al. THE TREATMENT OF STREPTOCOCCAL INFECTIONS IN MICE WITH 4:4'DIAMINODIPHENYLSULPHONE , 1937 .
[73] E. Nduati,et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. , 2000, The Journal of infectious diseases.
[74] Giulio Rastelli,et al. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach. , 2004, Journal of medicinal chemistry.
[75] J. Critchley,et al. Chlorproguanil-dapsone for treating uncomplicated malaria. , 2004, The Cochrane database of systematic reviews.
[76] C. Sibley,et al. Mutagenesis of dihydrofolate reductase from Plasmodium falciparum: analysis in Saccharomyces cerevisiae of triple mutant alleles resistant to pyrimethamine or WR99210. , 2001, Molecular and biochemical parasitology.
[77] T. Triglia,et al. The mechanism of resistance to sulfa drugs in Plasmodium falciparum. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[78] J. E. Hyde,et al. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. , 1990, Pharmacology & therapeutics.
[79] E. Nduati,et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania , 2001, The Lancet.
[80] J. Kublin,et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. , 2002, The Journal of infectious diseases.
[81] G. Peters,et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. , 1999, Cancer research.
[82] A. Breckenridge,et al. In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs , 1995, Antimicrobial agents and chemotherapy.
[83] E. Stokstad,et al. SYNTHESIS OF A COMPOUND IDENTICAL WITH THE L. CASEI FACTOR ISOLATED FROM LIVER. , 1945, Science.
[84] M. Kris,et al. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors , 2006, Cancer Chemotherapy and Pharmacology.
[85] G. Hitchings,et al. ANTAGONISTS OF NUCLEIC ACID DERIVATIVES I. THE LACTOBACILLUS CASEI MODEL , 1950 .
[86] A. E. Yeo,et al. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[87] B. Sharp,et al. Intercontinental Spread of Pyrimethamine-Resistant Malaria , 2004, Science.
[88] D. Fidock,et al. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[89] P. Rathod,et al. Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro , 1989, Antimicrobial Agents and Chemotherapy.
[90] S. Bahr,et al. In vitro activities of the biguanide PS-15 and its metabolite, WR99210, against cycloguanil-resistant Plasmodium falciparum isolates from Thailand , 1997, Antimicrobial agents and chemotherapy.
[91] D. Wallace. MALARIA IN THE AUSTRALIAN ARMY IN SOUTH VIETNAM , 1973, The Medical journal of Australia.
[92] W. Sirawaraporn,et al. Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum. , 2000, Journal of medicinal chemistry.
[93] P. Rathod,et al. Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum , 1992, Antimicrobial Agents and Chemotherapy.
[94] W. Peters,et al. Chemotherapy and drug resistance in malaria. , 1970 .
[95] K. Marsh,et al. Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[96] K. Srivastava,et al. Synthesis of 2,4,6-trisubstituted pyrimidines as antimalarial agents. , 2005, Bioorganic & medicinal chemistry.
[97] D. Kyle,et al. Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. , 1997, Annals of Tropical Medicine and Parasitology.
[98] I. Bygbjerg,et al. Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes. , 2005, The American journal of tropical medicine and hygiene.
[99] I. McGregor,et al. Pyrimethamine and Sulphadiazine in Treatment of Malaria , 1963, British medical journal.
[100] D. L. Jagt,et al. In vitro susceptibilities of Plasmodium falciparum to compounds which inhibit nucleotide metabolism , 1990, Antimicrobial Agents and Chemotherapy.
[101] Yongyuth Yuthavong,et al. Insights into antifolate resistance from malarial DHFR-TS structures , 2003, Nature Structural Biology.
[102] R. Michel. [Comparative study of the association of sulfalene and pyrimethamine and of sulfalene alone in mass chemoprophylaxis of malaria]. , 1968, Medecine tropicale : revue du Corps de sante colonial.
[103] W. Sirawaraporn,et al. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[104] N. Saravia,et al. Frequency of the Asn-108 and Thr-108 point mutations in the dihydrofolate reductase gene in Plasmodium falciparum from southwest Colombia. , 1998, The American journal of tropical medicine and hygiene.
[105] C. Plowe,et al. Kenyan Plasmodium falciparum Field Isolates: Correlation between Pyrimethamine and Chlorcycloguanil Activity In Vitro and Point Mutations in the Dihydrofolate Reductase Domain , 1998, Antimicrobial Agents and Chemotherapy.
[106] D. Greenwood. Conflicts of interest: the genesis of synthetic antimalarial agents in peace and war. , 1995, The Journal of antimicrobial chemotherapy.
[107] J. E. Hyde,et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? , 2001, Trends in parasitology.
[108] S. Jaffar,et al. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[109] Kevin Marsh,et al. In Vitro Activities of 2,4-Diaminoquinazoline and 2,4-Diaminopteridine Derivatives against Plasmodium falciparum , 2004, Antimicrobial Agents and Chemotherapy.
[110] P. Rathod,et al. Divergent Regulation of Dihydrofolate Reductase Between Malaria Parasite and Human Host , 2002, Science.
[111] W. Peters,et al. The antimalarial activity of N-benzyloxydihydrotriazines. I. The activity of clociguanil (BRL 50216) against rodent malaria, and studies on its mode of action. , 1980, Annals of tropical medicine and parasitology.
[112] R. Girdwood,et al. Folic acid in the treatment of the sprue syndrome. , 1947, Lancet.
[113] B. Bergmann,et al. Pyrimethamin-resistantPlasmodium falciparum lack cross-resistance to methotrexate and 2,4-diamino-5-(substituted benzyl) pyrimidines , 2004, Parasitology Research.
[114] J. Wolff,et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.
[115] E. Nduati,et al. 2,4-Diaminopteridine-Based Compounds as Precursors for De Novo Synthesis of Antifolates: a Novel Class of Antimalarials , 2005, Antimicrobial Agents and Chemotherapy.
[116] G. Hitchings,et al. 2:4-diaminopyrimidines- a new series of antimalarials. , 1951, British journal of pharmacology and chemotherapy.
[117] W. Milhous,et al. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[118] Yongyuth Yuthavong,et al. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. , 2004, Journal of medicinal chemistry.
[119] P. Rathod,et al. Susceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase , 1994, Antimicrobial Agents and Chemotherapy.
[120] A. Hoffbrand,et al. The history of folic acid , 2001, British journal of haematology.
[121] J. Hyde,et al. Translational up-regulation of antifolate drug targets in the human malaria parasite Plasmodium falciparum upon challenge with inhibitors. , 2004, Molecular and biochemical parasitology.
[122] W. Watkins,et al. Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. , 1985, Molecular and biochemical parasitology.
[123] W. Milhous,et al. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. , 1993, The American journal of tropical medicine and hygiene.
[124] K. Kain,et al. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[125] E. Nduati,et al. Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[126] A. Laing. Studies on the chemotherapy of malaria. I. The treatment of overt falciparum malaria with potentiating combinations of pyrimethamine and sulphormethoxine or dapsone in The Gambia. , 1970, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[127] W. Sirawaraporn,et al. Mutational analysis of Plasmodium falciparum dihydrofolate reductase: the role of aspartate 54 and phenylalanine 223 on catalytic activity and antifolate binding. , 2002, Molecular and biochemical parasitology.